Europe's medicines watchdog said it has started reviewing China's Sinovac coronavirus jab, a process that could lead to eventual approval for the European market.
The EMA's human medicines committee's “decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies,” the Amsterdam-based agency said, according to AFP.
“These studies suggest that the vaccine triggers the production of antibodies that target Sars-CoV-2, the virus that causes Covid-19, and may help protect against the disease,” it said in a statement.
